Table 3 Treatment-emergent adverse events (TEAEs) occurring in ≥ 10% of patients and ≥ grade 3 TEAEs in > 3%
Safety population (n = 47) | ||
|---|---|---|
| Â | Any grade | Grade 3 or more |
Nausea | 37 (78.7%) | 5 (10.6%) |
Vomiting | 31 (66.0%) | 5 (10.6%) |
Decreased hemoglobin | 24 (51.1%) | - |
Acid reflux | 24 (51.1%) | 3 (6.4%) |
Leukopenia | 19 (40.4%) | 3 (6.4%) |
Swallowing difficulty | 18 (38.3%) | 3 (6.4%) |
Thrombocytopenia | 18 (38.3%) | 2 (4.3%) |
Hypokalemia | 14 (29.8%) | 3 (6.4%) |
Neutropenia | 13 (27.7%) | 8 (17.0%) |
Bone marrow suppression | 12 (25.5%) | 6 (12.8%) |
Increased alanine aminotransferase | 10 (21.3%) | - |
Fatigue | 10 (21.3%) | - |
Proteinuria | 9 (19.1%) | - |
Lymphocytopenia | 7 (14.9%) | 3 (6.4%) |
Constipation | 7 (14.9%) | - |
Hyponatremia | 7 (14.9%) | - |
Anorexia | 7 (14.9%) | - |
Diarrhea | 6 (12.8%) | 2 (4.3%) |
Hypochloridemia | 6 (12.8%) | - |
Hypertension | 6 (12.8%) | - |
Hypocalcemia | 5 (10.6%) | - |
Increased indirect bilirubin | 5 (10.6%) | - |
Lower limb ache | 5 (10.6%) | - |
Increased aspartate aminotransferase | 5 (10.6%) | - |
Chest pain | 4 (8.5%) | 3 (6.4%) |